Merck to buy vaccine plant from WuXi Biologics: report
Source: SeekingAlpha
2025-01-06 11:24:08 ET
More on Merck
- Merck: A Low-Hanging Fruit To Pick
- Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time
- Merck: Buy Opportunity Backed By Growth
- Brand prescription drugs to rise an average 4.5% in 2025
- Merck gets U.K. approval for sotatercept for PAH
Read the full article on Seeking Alpha
For further details see:
Merck to buy vaccine plant from WuXi Biologics: report
Merck & Company Inc.
NASDAQ: MRK
MRK Trading
1.11% G/L:
$116.48 Last:
2,106,719 Volume:
$116.92 Open:
MRK Latest News
March 05, 2026 10:20:00 am
Forget ImmunityBio: This Big?Cap Pharma Is the Safer Play on Next?Gen Cancer Therapies
March 03, 2026 09:00:00 am
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
MRK Stock Data
$291,612,827,755
2,457,202,311
0.02%
2165
N/A
Pharmaceuticals
Healthcare
US
Rahway
